Epizyme

OverviewSuggest Edit

Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. 

Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.

TypePublic
Founded2007
HQCambridge, MA, USMap
Websiteepizyme.com
Employee Ratings3.3More
View Jobs (2)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)203(+64%)
Job Openings2
Revenue (FY, 2020)$15.8 M(-33%)
Share Price (Jun 2021)$8.5
Cybersecurity ratingCMore

Key People/Management at Epizyme

David M. Mott

David M. Mott

Chairman
Robert Bazemore

Robert Bazemore

President and Chief Executive Officer, Director
Matthew Ros

Matthew Ros

Executive Vice President, Chief Strategy and Business Officer
John Weidenbruch

John Weidenbruch

General Counsel
Jeffery Kutok

Jeffery Kutok

Chief Scientific Officer
Shefali Agarwal

Shefali Agarwal

Executive Vice President, Chief Medical and Development Officer
Show more

Epizyme Office Locations

Epizyme has an office in Cambridge
Cambridge, MA, US (HQ)
400 Technology Square, 400 Technology Square
Show all (1)

Epizyme Financials and Metrics

Epizyme Revenue

Epizyme's revenue was reported to be $15.76 m in FY, 2020
USD

Revenue (Q1, 2021)

7.6m

Gross profit (Q1, 2021)

4.8m

Gross profit margin (Q1, 2021), %

62.6%

Net income (Q1, 2021)

(70.3m)

EBIT (Q1, 2021)

(64.3m)

Market capitalization (11-Jun-2021)

869.9m

Closing stock price (11-Jun-2021)

8.5

Cash (31-Mar-2021)

73.7m

EV

1.0b
Epizyme's current market capitalization is $869.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

21.7m23.8m15.8m

Revenue growth, %

(40%)(94%)213%

Cost of goods sold

5.1m

Gross profit

10.7m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

12.0m7.9m5.9m5.7m1.4m2.5m3.6m7.6m

Cost of goods sold

614.0k1.0m1.6m2.9m

Gross profit

740.0k1.4m2.0m4.8m

Gross profit Margin, %

55%59%55%63%
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

123.6m190.1m208.3m77.9m226.7m86.7m139.5m168.2m

Accounts Receivable

33.7m2.1m262.0k23.0k382.0k20.1m2.6m3.1m

Prepaid Expenses

2.4m2.8m4.5m9.0m12.2m15.5m17.9m

Inventories

6.5m10.5m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

148.7m139.6m237.1m229.9m211.7m244.5m236.7m229.9m312.7m89.5m66.0m64.4m88.5m219.8m130.3m67.9m66.3m144.3m45.9m93.5m179.3m117.2m93.4m73.7m

Accounts Receivable

7.8m2.2m8.2m2.2m2.1m365.0k723.0k177.0k176.0k60.0k6.2m8.0k25.0k25.0k24.0k12.3m13.0m13.3m12.0m1.6m1.7m4.6m9.8m

Prepaid Expenses

2.0m2.1m2.1m2.7m3.3m2.5m2.0m2.5m5.5m7.9m5.5m8.8m8.6m10.0m8.9m8.5m7.0m15.2m14.1m16.1m22.6m21.0m18.5m16.9m

Inventories

1.7m9.9m8.2m14.8m
show all
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.5m)(55.0m)(132.4m)(110.2m)(134.3m)(123.6m)(170.3m)(231.7m)

Depreciation and Amortization

703.0k742.0k1.4m1.6m1.6m1.1m4.0m

Inventories

(10.5m)

Accounts Payable

1.6m3.6m(3.6m)341.0k2.0m(2.4m)3.4m1.5m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(9.7m)(19.4m)(6.9m)(20.3m)(40.0m)(61.3m)(87.1m)(110.1m)(22.9m)(50.9m)(75.2m)(32.5m)(60.5m)(98.1m)(34.1m)(63.2m)(100.7m)(29.3m)(77.8m)(113.9m)(50.9m)(109.4m)(165.5m)(70.3m)

Depreciation and Amortization

363.0k534.0k169.0k362.0k548.0k260.0k653.0k1.1m389.0k791.0k1.2m411.0k824.0k1.2m361.0k582.0k804.0k207.0k416.0k626.0k512.0k1.4m2.7m1.3m

Inventories

(1.7m)(9.9m)(8.2m)(4.4m)

Accounts Payable

290.0k364.0k(1.3m)(142.0k)1.1m(3.2m)(5.2m)(5.3m)(2.4m)(980.0k)(1.3m)1.9m4.6m366.0k226.0k4.0m(701.0k)3.2m2.1m573.0k(2.7m)(4.2m)(1.3m)(4.8m)
show all
USDQ2, 2013

Financial Leverage

1.7 x
Show all financial metrics

Epizyme Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

Epizyme Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

Learn more about our premium products
CSRHub logo

Epizyme Online and Social Media Presence

Epizyme's Trends

Embed Graph

Epizyme News and Updates

May 07, 2021

Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?

NEW YORK, May 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPZM, AMC, EVFM, NOK, and ARQT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
May 07, 2021

SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug

Shares of Epizyme Inc. were up 11.0% in premarket trading on Friday after SVB Leerink upgraded the company's stock to outperform, from market perform, citing Tazverik's potential opportunity in the follicular lymphoma market. Analyst Andrew Berens told investors that the drug's potential as a "main…
June 18, 2018

Epizyme (EPZM) Tazemetostat Interim Phase 2 Data in Follicular Lymphoma - Slideshow

June 18, 2018

Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold

May 18, 2018

Epizyme (EPZM) Clinical Data Conference Call - Slideshow

April 24, 2018

Biotech Analysis Central Pharma News: Orexigen's Last Resort, Epizyme's Partial Clinical Hold, Eli Lilly And Incyte's Mixed Advisory Panel Vote

Show more

Epizyme Blogs

June 16, 2021

Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients

EZH2Now Testing Program is first of its kind to offer national single gene testing for EZH2 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 16, 2021-- Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched
May 25, 2021

Epizyme to Participate in Jefferies Virtual Healthcare Conference

Epizyme to Participate in Jefferies Virtual Healthcare Conference Content Import Tue, 05/25/2021 - 06:31 Epizyme to Participate in Jefferies Virtual Healthcare Conference May 25, 2021 This release is a backfill from a News Wire General …
May 12, 2021

Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June

Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June Content Import Wed, 05/12/2021 - 16:01 Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Confere…
May 06, 2021

Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results

Total Revenue of $7.6 Million for 1Q 2021; TAZVERIK ® Net Product Revenues of $6.2 Million Ongoing TAZVERIK Clinical Trials in both Follicular Lymphoma and Prostate Cancer Demonstrate Encouraging Preliminary Safety and Activity Data Investigational New Drug (IND) Submission for Novel SETD2
April 29, 2021

Epizyme Announces Date of First Quarter 2021 Financial Results

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2021-- Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter
March 02, 2021

Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy Preliminary Safety and Activity Data from Ongoing Clinical Trials for TAZVERIK ® Combinations in Follicular Lymphoma and Prostate Cancer Support Advancement Basket Trials
Show more

 Epizyme Frequently Asked Questions

  • When was Epizyme founded?

    Epizyme was founded in 2007.

  • Who are Epizyme key executives?

    Epizyme's key executives are David M. Mott, Robert Bazemore and Matthew Ros.

  • How many employees does Epizyme have?

    Epizyme has 203 employees.

  • What is Epizyme revenue?

    Latest Epizyme annual revenue is $15.8 m.

  • What is Epizyme revenue per employee?

    Latest Epizyme revenue per employee is $77.6 k.

  • Who are Epizyme competitors?

    Competitors of Epizyme include EUSA Pharma, Chugai Pharmaceutical and Ascentage Pharma.

  • Where is Epizyme headquarters?

    Epizyme headquarters is located at 400 Technology Square, 400 Technology Square, Cambridge.

  • Where are Epizyme offices?

    Epizyme has an office in Cambridge.

  • How many offices does Epizyme have?

    Epizyme has 1 office.